Abstract
The peptide growth factors IGF-I and IGF-II not only play a role in the development of the mammary gland but are also implicated in breast cancer. Several reagents disrupting IGF signaling have been developed and clinical trials validating IGF signaling as a target in cancer therapy are underway. This review highlights the approaches to inhibiting IGF signaling in breast cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 27-39 |
Number of pages | 13 |
Journal | Journal of mammary gland biology and neoplasia |
Volume | 11 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2006 |
Keywords
- Antibodies
- Breast cancer
- Insulin-like growth factors
- Small molecule inhibitors
- Targeted therapy
- TypeI IGF receptor